Evaluating Tocilizumab Added to Standard Treatment for Chronic Active Antibody Mediated Rejection in Kidney Transplant Patients

What this Trial Is About

Chronic active antibody mediated rejection CAMR is a serious challenge for kidney transplant recipients, as it does not respond well to standard treatments for acute antibody mediated rejection AMR. Each year, about 5,000 kidney transplants fail in the United States due to CAMR, and only around 20% of grafts survive two years after CAMR diagnosis. Current therapies including plasmapheresis, IVIG, rituximab, and anti-plasma cell treatments like bortezomib have not consistently improved outcomes, highlighting the need for new treatment approaches. This trial is an open-label, randomized clinical study evaluating the safety and effectiveness of adding Tocilizumab to the standard treatment regimen of plasmapheresis, IVIG, and rituximab in patients with CAMR after kidney transplantation. Participants are assigned to receive either the standard care alone or standard care plus Tocilizumab. The study aims to compare these two treatment approaches to better target donor specific antibody-producing cells and reduce CAMR effects. Participants will be monitored for about one year, during which researchers will assess kidney function by measuring the glomerular filtration rate GFR. The study includes regular evaluations to track treatment safety and effectiveness. By closely following participants, the trial seeks to determine whether adding Tocilizumab improves kidney graft survival and overall health outcomes in CAMR patients.

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab